The Global Lung Cancer Coalition (GLCC) consists of 41 patient advocacy groups based in 40 countries, and it is dedicated to improving disease outcomes in lung cancer. A year after COVID-19 lockdowns were imposed on most countries in the world, the GLCC administered a 24-question survey to its members. The survey questions related to 5 major themes: level of patient demand for services during the pandemic, type of information patients sought, any changes to the provision of services due to the pandemic, the impact of these changes to the organisations’ financial standing, and information regarding access of lung cancer patients to COVID-19 vaccinations.
Prof. Matthew Peters (Concord Hospital, Australia) presented the survey outcomes. Among the 19 organisations that responded to the survey (which closed March 2021), 63% reported a 20–80% higher number of patient enquiries during the pandemic. The same percentage of respondents reported that there had been a shift in the type of support that patients were requesting; namely, information about the safety and availability of COVID-19 vaccination services and how COVID-19 would impact their treatment. Most respondents reported that they had begun to offer new digital services to cater to these new demands: webinars, online emotional support groups, and increased website content. At the time of the survey close, 79% of survey respondents indicated that COVID-19 vaccinations were available in their country.
While 6 organisations reported an increase in governmental funding during the pandemic, 7 reported no change. The GLCC suggested that more funding of patient organisations will be required as they continue to adapt to and serve the evolving needs of patients with lung cancer during the COVID-19 pandemic.
- Peters M. Considering the continued impact of the COVID-19 pandemic on patient advocacy and support organisations. MA 05.03, WCLC 2021, 8–14 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Lung Cancer Europe patient survey identifies gaps in lung cancer care Next Article
Prognostic factors in immunotherapy for advanced lung cancer »
« Lung Cancer Europe patient survey identifies gaps in lung cancer care Next Article
Prognostic factors in immunotherapy for advanced lung cancer »
Table of Contents: WCLC 2021
Featured articles
Atezolizumab promising for treating NSCLC brain metastases
Novel Therapy Approaches
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
COVID-19
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Evidence-Based Advocacy
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Response Predictors
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
Related Articles
December 9, 2021
Immune-mediated diseases tied to risk of cancer
June 25, 2019
Electromagnetic navigation bronchoscopy
September 21, 2021
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com